Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

BACKGROUND: Tumors with deficient homologous repair are sensitive to PARP inhibitors such as olaparib which is known to have immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) which inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. Tremelimumab (T)...

Descripción completa

Detalles Bibliográficos
Autores principales: Fumet, Jean-David, Limagne, Emeric, Thibaudin, Marion, Truntzer, Caroline, Bertaut, Aurélie, Rederstorff, Emilie, Ghiringhelli, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418426/
https://www.ncbi.nlm.nih.gov/pubmed/32778095
http://dx.doi.org/10.1186/s12885-020-07253-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418426/
https://www.ncbi.nlm.nih.gov/pubmed/32778095
http://dx.doi.org/10.1186/s12885-020-07253-x

Ejemplares similares